Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) – Equities researchers at HC Wainwright issued their FY2027 EPS estimates for Harpoon Therapeutics in a research note issued to investors on Wednesday, March 29th. HC Wainwright analyst S. Ramakanth expects that the company will earn $0.23 per share for the year. HC Wainwright has a “Buy” rating […]
HPN217 and HPN328 enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023 Completion of $25 million preferred. | March 27, 2023
Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
07.02.2023 - SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will present at the virtual SVB .